Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | ITK | Q08881 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18385063 | 1.00 | EGFR (0.43) | EGFRITK | |
| SCHEMBL25830630 | 0.83 | KCNH3 (0.46) | — | |
| SCHEMBL18385065 | 0.83 | KCNH3 (0.46) | — | |
| SCHEMBL18391969 | 0.83 | KCNH3 (0.58) | — | |
| SCHEMBL17130325 | 0.76 | IDO1 (0.53) | EGFR | |
| SCHEMBL17130323 | 0.76 | CDC25B (0.45) | EGFRITK | |
| SCHEMBL12387589 | 0.73 | SYK (0.48) | EGFR | |
| SCHEMBL18391971 | 0.71 | CDC25B (0.48) | EGFR | |
| SCHEMBL13223236 | 0.71 | CDC25B (0.48) | EGFR | |
| SCHEMBL16983519 | 0.71 | CA9 (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701429-B2 | Targeted drug delivery through affinity based linkers | Akamara Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701429-B2 | Targeted drug delivery through affinity based linkers | Akamara Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20200199249-A1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | Akamara Therapeutics, Inc. (US) | 2020-06-25 | — | — | US | disclosed |
| US-20170014528-A1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | INVICTUS ONCOLOGY PVT. LTD. (IN) | 2017-01-19 | — | — | US | disclosed |
| WO-2015148126-A1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | INVICTUS ONCOLOGY PVT. LTD. (IN) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170014528-A1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | ABCG2, ADAM8, TIE1 | EGFR 50/4885ITK 1762/4885 |
| US-11701429-B2 | Targeted drug delivery through affinity based linkers | ABCG2, FCGR2A, ABCB1 | EGFR 49/4885ITK 4233/4885 |
| US-20200199249-A1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | ABCG2, FCGR2A, ABCB1 | EGFR 49/4885ITK 4233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.